IOL Chemicals Reports Strong Q2 FY27 Financial Results and Growth Initiatives
IOL Chemicals & Pharmaceuticals Ltd · Investor Presentation · 02 Nov 2026, 1:21 pm
IOL Chemicals Reports Strong Q2 FY27 Financial Results and Growth Initiatives IOL Chemicals reported standalone revenue of ₹795.0 Cr for Q2 FY27, up 40.1% YoY (5.1% QoQ), while EBITDA jumped 79.6% YoY to ₹114.9 Cr with margins expanding to 14.4%. PAT surged 116.8% YoY to ₹65.0 Cr. For H1 FY27, revenue reached ₹1551.3 Cr (+38.6% YoY) and PAT stood at ₹129.5 Cr (+102.5% YoY). The company announced a ₹495 Cr capex program across three strategic projects: expanding Ibuprofen capacity by 6,000 MTPA (₹350 Cr), entering CDMO formulations (₹110 Cr), and a specialty chemicals tolling unit (₹35 Cr).
Original exchange filing (PDF)
More announcements from IOL Chemicals & Pharmaceuticals Ltd
- Clarification on increase in Volume · 11 Nov 2026
- The Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 11 Nov 2026
- Transcript of Earning Call on the Q2 & H1 FY27 Financial Results · 05 Nov 2026
- Audio Recording of Earnings Call on the Q2 & H1 FY 27 Financial Results · 02 Nov 2026
- Press Release · 31 Oct 2026
- Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 · 30 Oct 2026
- Submission of Financial Results · 30 Oct 2026
- IOL Chemicals and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 30 Oct 2026
